Legal & General Group PLC Arbutus Biopharma Corp Transaction History

Legal & General Group PLC

$440 Billion
Q2 2024

A detailed history of Legal & General Group PLC transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Legal & General Group PLC holds 15,248 shares of ABUS stock, worth $58,399. This represents 0.0% of its overall portfolio holdings.

Number of Shares

15,248

Previous 12,308 23.89%

Holding current value

$58,399

Previous $31,000 51.61%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$2.52 - $3.63 $7,408 - $10,672	2,940 Added 23.89%	15,248 $47,000
Q3 2023 Nov 14, 2023	SELL	$1.9 - $2.27 $3,323 - $3,970	-1,749 Reduced 12.44%	12,308 $24,000
Q2 2023 Aug 14, 2023	BUY	$2.24 - $3.06 $4,164 - $5,688	1,859 Added 15.24%	14,057 $32,000
Q3 2022 Nov 14, 2022	BUY	$1.88 - $2.88 $3,256 - $4,988	1,732 Added 16.55%	12,198 $23,000
Q2 2022 Aug 22, 2022	BUY	$1.98 - $3.17 $4,979 - $7,972	2,515 Added 31.63%	10,466 $28,000
Q1 2022 May 16, 2022	BUY	$2.42 - $3.98 $3,450 - $5,675	1,426 Added 21.85%	7,951 $24,000
Q3 2021 Nov 15, 2021	BUY	$2.65 - $4.62 $752 - $1,312	284 Added 4.55%	6,525 $28,000
Q2 2021 Aug 12, 2021	BUY	$2.5 - $3.51 $15,602 - $21,905	6,241 New	6,241 $19,000
Q3 2019 Nov 13, 2019	SELL	$1.34 - $2.4 $7,030 - $12,592	-5,247 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$3.41 - $4.57 $78,975 - $105,841	-23,160 Reduced 81.53%	5,247 $19,000
Q4 2018 Feb 15, 2019	BUY	$3.5 - $9.66 $13,534 - $37,355	3,867 Added 15.76%	28,407 $109,000
Q3 2018 Nov 20, 2018	BUY	$7.85 - $12.35 $151,450 - $238,268	19,293 Added 367.7%	24,540 $232,000
Q2 2018 Aug 10, 2018	BUY	$5.0 - $7.35 $26,235 - $38,565	5,247 New	5,247 $38,000

Others Institutions Holding ABUS

# of Institutions

137

Shares Held

95.4M

Call Options Held

3.44M

Put Options Held

377K

View Full List

About Arbutus Biopharma Corp

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $574M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

More about ABUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Account

Legal & General Group PLC Arbutus Biopharma Corp Transaction History